~~<i id='36844BAC56'><strike id='36844BAC56'><tt id='36844BAC56'><pre id='36844BAC56'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

focus

author：explore 2025-09-14 10:02:57 - browse：571

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： U.K. decision on ALS drug has neurologists, advocates up in arms

leisure time

explore

hotspot

leisure time

hotspot

leisure time

MollyFergusonforSTATWhileanincreasinglyanxiousworldwatchedanewcoronavirusspreadacrosstheglobeinearly

WSS

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Scientists uncover potential path to treating deadly childhood tumor

National associations that represent hospice owe an apology

Trans patients at the end of life deserve respect and dignity

California store owner shot dead in dispute over displaying Pride flag: Police

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Wikipedia

focus

leisure time

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

U.K. decision on ALS drug has neurologists, advocates up in arms

Drug repurposing or repositioning? The language matters

FDA greenlights medical device to combat bladder issues

In Memoriam: Notable people who died in 2023

Republican states more likely to report Covid vaccine side effects

In age of alternative facts, a scholarly course on calling out crap

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Trump demands the U.S. pay no more for drugs than other countries … again

How to make over

explore

How the drug

Roche's accidental data boosts hopes for anti

Covid silver lining: Unprecedented look at human immune system

UnitedHealth, in a surprise, takes aim at Steward’s physician group

As obesity drug market grows, telehealth companies court payers

Florida Supreme Court upholds state's abortion ban

hotspot

leisure time

hotspot

leisure time